Type 2 Diabetes — Controlling the Epidemic (Episode 4 of 4) | NEJM

Drs. Jane E.B. Reusch and E. Dale Abel discuss old and new pharmacological therapies for type 2 diabetes, including benefits, side effects, and costs.

In this fourth episode of “Type 2 Diabetes — Controlling the Epidemic,” a four- part Double Take video miniseries from the New England Journal of Medicine, Drs. Jane E.B. Reusch (University of Colorado) and E. Dale Abel (UCLA) describe old and new drugs available for diabetes therapy and discuss their benefits and side effects. Dr. Monica Peek (University of Chicago) and other experts reflect on the cost barriers faced by patients with diabetes and strategies used to overcome those challenges. For further reading, the following articles, referenced in this video, are available at NEJM.org, where you can also watch Quick Take video summaries of the research articles: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin (Rosenstock et al., in the July 27, 2023, issue; nejm.org/doi/full/10.1056/NEJMoa2303208 ), Building a Better Insulin — Whom Will It Help? (Reusch, in the July 27, 2023, issue; nejm.org/doi/full/10.1056/NEJMe2307280 ), Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., in the March 18, 2021, issue; nejm.org/doi/full/10.1056/NEJMoa2032183 ), Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al., in the July 21, 2022, issue; nejm.org/doi/full/10.1056/NEJMoa2206038 ), and Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (Gerstein et al., in the September 2, 2021, issue; nejm.org/doi/full/10.1056/NEJMoa2108269 ). The New England Journal of Medicine is the world’s leading general medical journal. Continuously published for over 200 years, NEJM publishes peer-reviewed research along with interactive clinical content for physicians, educators, and the global medical community at NEJM.org. #diabetes #medicaleducation #publichealth